DERM vs. ASMB, VTVT, LABP, RLYB, YS, MNOV, SCYX, SLS, VHAQ, and CARM
Should you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Assembly Biosciences (ASMB), vTv Therapeutics (VTVT), Landos Biopharma (LABP), Rallybio (RLYB), YS Biopharma (YS), MediciNova (MNOV), SCYNEXIS (SCYX), SELLAS Life Sciences Group (SLS), Viveon Health Acquisition (VHAQ), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical preparations" industry.
Journey Medical (NASDAQ:DERM) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
Assembly Biosciences received 240 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 59.21% of users gave Assembly Biosciences an outperform vote.
Assembly Biosciences has a net margin of 0.00% compared to Journey Medical's net margin of -4.87%. Journey Medical's return on equity of -34.08% beat Assembly Biosciences' return on equity.
Journey Medical presently has a consensus target price of $8.50, suggesting a potential upside of 137.43%. Given Journey Medical's stronger consensus rating and higher probable upside, research analysts clearly believe Journey Medical is more favorable than Assembly Biosciences.
In the previous week, Assembly Biosciences had 26 more articles in the media than Journey Medical. MarketBeat recorded 30 mentions for Assembly Biosciences and 4 mentions for Journey Medical. Journey Medical's average media sentiment score of 0.24 beat Assembly Biosciences' score of 0.08 indicating that Journey Medical is being referred to more favorably in the media.
Journey Medical has higher revenue and earnings than Assembly Biosciences. Journey Medical is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.
7.3% of Journey Medical shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 19.4% of Journey Medical shares are held by insiders. Comparatively, 5.1% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Journey Medical has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Summary
Journey Medical beats Assembly Biosciences on 12 of the 18 factors compared between the two stocks.
Get Journey Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Journey Medical Competitors List
Related Companies and Tools
